Drug Solutions Podcast: Realizing AI’s Potential
Latest News – We’re pleased to share that our CEO Adam Sherlock has been featured on Pharmaceutical Technology‘s Drug Solutions podcast joining industry experts to discuss artificial intelligence’s transformative potential in the bio/pharmaceutical industry and how AI and machine learning are shaping the future of drug development. Listen to the Full Episode Here
High-profile CEO appointment signals major new growth phase for class-leading pharmacovigilance specialist Qinecsa
Veteran safety & PV leader Adam Sherlock will capitalize on Qinecsa’s deep domain expertise and comprehensive technology-powered solutions to pharma’s most complex product safety challenges London, UK – October 8th, 2024 – Qinecsa, the global, class leader in technology-powered pharmacovigilance services, has announced the appointment of life sciences safety services mover and shaker Adam […]
Qinecsa Announces World Drug Safety Congress Americas Sponsorship
We are thrilled to announce that Qinecsa will be sponsoring the World Drug Safety Congress America 2024! THE LARGEST DRUG SAFETY EVENT IN THE WORLD The World Drug Safety Congress Americas convenes top executives and key stakeholders in the biopharmaceutical sector to address critical issues in drug safety, pharmacovigilance, and medical device safety. Our team […]
What is Pharmacovigilance?
Pharmacovigilance is a critical component of the medicinal product lifecycle, focusing on ensuring the safety and efficacy of medicinal products from pre-clinical development through post-marketing surveillance. The primary goals of pharmacovigilance are to enhance patient safety, manage risks, and strengthen public health and trust in therapeutic products. Regulatory bodies mandate rigorous vigilance to detect and […]
Qinecsa Sponsors the World Drug Safety Congress Europe
We are thrilled to announce that Qinecsa will be sponsoring the World Drug Safety Congress Europe 2024, marking our third year! EUROPE’S MOST EXCITING DRUG SAFETY & PV EVENT The World Drug Safety Congress Europe is where key communities and industries come together to discuss the latest advancements in drug safety. From exploring the use […]
Streamline AE, PQC & MI call handling operations with Reportum
Call centres are typically responsible for a high percentage of safety report entry. However, the nature of the reporting process means it is hard to control, often involving complex fixed pdf forms that can lead to incomplete data and require follow-up to achieve the desired level of data quality. Reportum® is a highly scalable, centralised […]
Standardise safety data collection with Reportum
Understanding patient safety is an essential element of Patient Support Programs. However, traditional safety reporting systems involve multi-step manual processes that often result in compliance failures and late or unreported cases. Reportum® is a highly scalable, centralised solution that assists PSP nurse and call centre reporting to ensure standardised and complete data capture across third-party […]
Simplify safety reporting on-the-go with Reportum
Safety reporting is not a core focus for field-based staff, therefore inputting of reports is often completed at a later time. This means report entry is frequently incomplete and often delayed, which puts pressure on the safety team to comply with required timelines. Reportum® offers a simple, easy-to-use interface that guides the capture of relevant, […]
Capture patient data direct from source with Reportum
A complete picture of drug safety cannot be created if only part of the available data is captured, however the current adverse event capture process involves a maze of reporting routes across pharma companies and regional regulators. This creates a barrier to reporting, resulting in adverse events going unreported. Reportum® enables pharma to provide an […]
End-to-end PV Solutions: Small Pharma & Biotech
Through the input of industry leader members of the PV Insights Network, Qinecsa focuses on providing solutions to the safety challenges facing small pharmaceutical and biotech companies. With the acquisition of Insife, we have further expanded our services to address these unique end-to-end PV needs.
